MENLO PARK, Calif. and
SOUTH PLAINFIELD, N.J.,
Nov. 15, 2017 /PRNewswire/
-- Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in
long-read sequencing, and GENEWIZ, the leading global genomics
service provider, announce that Andrew
Ludlow, Ph.D. from the University of
Michigan, is the winner of the AACR SMRT® Grant. With this
SMRT Grant, Dr. Ludlow will receive Iso-Seq® analysis on the
PacBio® Sequel® System at the GENEWIZ laboratory to further his
investigation to understand the splicing of transcripts regulated
by NOVA1 in lung cancer cells.
Isoform sequence (Iso-Seq) analysis is a unique approach to RNA
sequencing that produces full-length cDNA sequences without
assembly. It is an ideal approach when investigating complex
transcriptomes, like human, to discover gene fusions, splice
variants, and novel isoforms.
Launched at the annual meeting for the American Association for
Cancer Research, the 2017 AACR SMRT Grant is co-sponsored by PacBio
and GENEWIZ. The program was open to cancer researchers around the
world with the winner being chosen by a panel of scientists. To see
a full list of SMRT Grant recipients visit:
www.pacb.com/smrtgrant.
PacBio and GENEWIZ have also teamed up on the ASHG SMRT Grant
which is open to scientific researchers around the world who are
looking to identify and characterize structural variants. Apply by
December 11, 2017 at
web.genewiz.com/pacbio-sv-grant.
"We are very excited to be partnering with GENEWIZ, one of our
newest Sequel platform service providers. Their extensive
experience delivering genome and transcriptome solutions to cancer
researchers makes them an ideal partner for showcasing the utility
of the newly simplified Iso-Seq method for full-length isoform
sequencing," said Kevin Corcoran,
Senior Vice President of Market Development for PacBio.
"By partnering with top technology providers like PacBio, we are
able to bring tens-of-thousands of research scientists around the
world access to new and novel technologies like long-read
sequencing. It is through this combination of state-of the-art
platforms, along with our proprietary approaches and seasoned team
of Ph.D.-level staff scientists, that we are helping our customers
advance their discoveries faster than ever before," said Dr.
Ginger Zhou, Vice President, Global
Next Generation Sequencing for GENEWIZ.
For more information about Iso-Seq analysis and the PacBio
Sequel platform, visit: www.pacb.com/isoseq
For more information on the GENEWIZ Iso-Seq early access
program, visit:
genewiz.com/Public/Services/Next-Generation-Sequencing/RNA-Seq
ABOUT PACIFIC BIOSCIENCES
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers
sequencing systems to help scientists resolve genetically complex
problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences' products
enable: de novo genome assembly to finish genomes
in order to more fully identify, annotate and decipher genomic
structures; full-length transcript analysis to improve annotations
in reference genomes, characterize alternatively spliced isoforms
in important gene families, and find novel genes; targeted
sequencing to more comprehensively characterize genetic variations;
and real-time kinetic information for epigenome characterization.
Pacific Biosciences' technology provides high accuracy, ultra-long
reads, uniform coverage, and the ability to simultaneously detect
epigenetic changes. PacBio® sequencing systems,
including consumables and software, provide a simple, fast,
end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
ABOUT GENEWIZ
GENEWIZ is a global leader in genomics services that enable
research scientists within pharmaceutical, biotechnology,
agriculture, environmental and clean energy, academic, and
government institutions to advance their discoveries. Customers
rely on our unique and proprietary genomics technologies and
services, backed by our specialized experts in DNA sequencing, gene
synthesis, molecular biology, high throughput sequencing,
bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield,
NJ, GENEWIZ is privately-held with a network of laboratories
in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; Los
Angeles, CA; San Francisco,
CA; and Seattle, WA.
International locations include Beijing, Suzhou, Tianjin, and Guangzhou China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit
www.genewiz.com, and connect with us on LinkedIn, Twitter,
Facebook, YouTube, WeChat, and Weibo.
View original
content:http://www.prnewswire.com/news-releases/pacbio-and-genewiz-announce-winner-of-the-2017-aacr-smrt-grant-300556861.html
SOURCE GENEWIZ